Balaji Amines Limited (BALAMINES) announced its unaudited financial results for the quarter and half year ended September 30th, 2026. The consolidated revenue for Q2 FY27 stood at ₹472 crore, up from ₹348 crore in Q2 FY26. The EBITDA was ₹106 crore compared to ₹67 crore in the same quarter last year. Net profit for the quarter was ₹67 crore, significantly higher than the ₹37 crore reported in Q2 FY26.

Financial Performance

The company’s total revenue for Q2 FY27 was ₹472 crore, a notable increase from ₹348 crore in Q2 FY26. The EBITDA margin stood at 22%, down from 26% in Q1 FY27 but up from 19% in Q2 FY26. The profit after tax (PAT) for the quarter was ₹67 crore, up from ₹37 crore in the previous year’s quarter. Diluted earnings per share (EPS) for Q2 FY27 stood at ₹20.76 per equity share, compared to ₹10.67 in Q2 FY26.

Growth Drivers

The company continues to strengthen its growth platform through capacity expansion and a focus on value-added specialty chemicals. Commercial production has commenced at the expanded Acetonitrile (ACN) facility, increasing installed capacity to 1,440 TPM. The upgraded plant incorporates advanced technology and enhanced process efficiencies, positioning the company to improve operational performance over the medium term.

The successful commissioning of the 100,000 TPA Dimethyl Ether (DME) plant, India’s first commercial-scale DME facility, has established the company in a high-potential import substitution market with applications spanning healthcare, personal care products, and fuel applications. The next phase of work is in the pipeline to establish a robust network of customers as the company has already studied the ever-expanding Aerosol market. Opportunities for export of DME are explored regularly.

The next product planned for commercialization is N-Methyl Morpholine (NMM), further expanding the specialty chemicals portfolio. In parallel, Balaji Speciality Chemicals is progressing with its expansion program that is aimed at increasing the share of high-value specialty chemicals. The Unit-I brownfield expansion, comprising EDA derivatives such as DETA, TETA, Piperazine, AEEA, and AEP, remains on track for commissioning during the end of FY27. The Unit-II greenfield project at MIDC, Chincholi, which will manufacture HCN, NaCN, EDTA, and EDTA-2Na, is targeted for commissioning in Q4 FY27.

On the performance, Mr. D. Ram Reddy, Managing Director, commented, ‘Q2 FY27 reflected resilient execution and steady progress on our strategic priorities. As we enter H2 FY27, our focus is firmly on driving higher utilization, improving operating efficiencies and translating recent investments into stronger earnings growth. The commissioning of the upgraded Acetonitrile (ACN) facility and the DME plant marks an important step in expanding our presence in value-added and import-substitution products. We are now focused on scaling these capacities and unlocking their full commercial potential. We have also improved the process of Di Isopropylamine (DIPA) as continuous efforts yielded this success. Overall, the volumes have dented due to various external factors, however, the company has leveraged its strength in stabilising the product portfolio to keep the top line stable and continuing the efforts to strengthen the bottom line. Our growth pipeline remains robust, with N-Methyl Morpholine (NMM) and multiple specialty chemical projects progressing as planned. These investments will further strengthen our specialty chemicals portfolio, enhance integration and expand our participation in high-growth end markets. With a stronger product mix, a visible expansion roadmap and a disciplined focus on execution, we remain confident in our ability to drive sustainable growth, improve earnings quality and create long-term value for shareholders.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Balaji Amines Limited

Balaji Amines Limited belongs to the Basic Materials › Specialty Chemicals sector. Here’s a quick read on where the business and the stock stand today.

Balaji falls 9.7% over three months and has not found a floor yet. Revenue contracts at -15.6% CAGR. That signals structural headwinds, not a short-term blip. The stock holds at 66% of its 52-week range with RSI at 45. In other words, neither side has a clear edge right now. The stock holds up despite -15.6% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Balaji Amines Limited.